Precision plasmid engineering for enhanced AAV tropism and safety.

Executive Summary

AAV capsid engineering via site-directed mutagenesis modifies plasmid DNA to introduce specific amino acid substitutions in the capsid protein. These modifications are designed to alter vector tropism for improved tissue-specific delivery and to reduce recognition by pre-existing neutralizing antibodies, directly addressing two primary obstacles in AAV vector development. The workflow integrates plasmid engineering, scalable vector production, and full analytical verification.

Frequently Asked Questions

What is site-directed mutagenesis for AAV?

Site-directed mutagenesis is a molecular biology technique used to make specific, targeted changes to a DNA sequence. In the context of AAV development, we apply it to the plasmid encoding the capsid proteins to introduce precise amino acid substitutions. This rational design approach allows for the engineering of novel capsids with desired characteristics, such as detargeting the liver or enhancing transduction of specific cell types.

How does capsid engineering improve tissue tropism?

The AAV capsid surface determines which cells and tissues the vector can effectively bind to and enter. By altering specific amino acid residues on the capsid surface, we can modify these binding properties. This allows for the creation of vectors that more efficiently target tissues of interest (e.g., central nervous system, muscle) while avoiding uptake by non-target organs, improving both efficacy and the safety profile.

What plasmid backbones are compatible with this service?

Our platform is compatible with a wide range of commercially available and custom AAV plasmid backbones. We provide consultation prior to project initiation to confirm compatibility and recommend any optimizations to the ITR, rep, and cap sequences to ensure high-titer, high-quality vector production following mutagenesis.

What is the typical turnaround time for a mutagenesis project?

Project timelines are established following an initial consultation to define the scope of mutagenesis and verification required. Subsequent research-grade AAV production aligns with our standard vector manufacturing timelines, managed within our >100,000 sq ft facility to maintain project continuity.

Engineering AAV Capsids to Overcome Biological Barriers

Pre-existing immunity and suboptimal tissue tropism remain significant challenges for many AAV programs. The host immune system, particularly T cells, can recognize and respond to capsid proteins, potentially limiting therapeutic benefit and preventing re-dosing. As outlined in reviews of AAV immunogenicity, understanding and mitigating these T cell responses is a primary objective for developing next-generation vectors (PMID: 28323492).

Rational capsid design, executed through precise DNA modifications, provides a direct path to addressing these limitations. By introducing targeted mutations at the plasmid level, we can engineer novel AAV capsids that evade immune recognition and exhibit highly specific tissue tropism. This approach moves beyond relying on naturally occurring serotypes and enables the development of vectors tailored to a specific therapeutic application.

Our process involves:

• Sequence Analysis & Design: In-silico analysis to identify key residues for modification based on structural data and therapeutic goals.

• Precision Mutagenesis: Introduction of single or multiple point mutations, insertions, or deletions into the cap gene plasmid.

• Sequence Verification: Sanger sequencing to confirm the intended modifications and ensure the integrity of the entire plasmid construct.

• Scalable Production: Manufacturing of the engineered AAV vector using our established adherent or suspension platforms.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption… Franklin Biolabs is an essential collaborator in our AAV-vector based gene therapy candidate development, and we hope to continue the partnership for years to come.”
– Biotech Partner

Featured Resource: Engineering Enhanced Capsids

This clip from our webinar, Vector Ready: Where AAV projects begin and how they succeed, details the factors for initiating AAV vector programs, with a focus on capsid engineering and preclinical safety profiling.

[FBL-VID-03-Approved_enhanced_capsid_engineering_clip.mp4]